Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553814 | 0.89 | TDP1 (0.56) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL15834222 | 0.88 | TDP1 (0.72) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL15440632 | 0.84 | ALDH1A1 (0.55) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL11669542 | 0.84 | TDP1 (0.47) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL25329286 | 0.83 | TDP1 (0.61) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL621983 | 0.83 | PKM (0.69) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL30105934 | 0.83 | PKM (0.69) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL7847617 | 0.83 | PKM (0.65) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL8683506 | 0.83 | PKM (0.56) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL1447280 | 0.83 | PKM (0.56) | KDM4ETDP1POLBCTDSP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877462-B1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-9133161-B2 | Processes for preparing isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133161-B2 | Processes for preparing isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133161-B2 | Processes for preparing isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2877462-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | Celgene Corporation (US) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014018866-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | WO | disclosed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| EP-0934307-B1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2011-04-27 | — | — | EP | disclosed |
| EP-2223920-A2 | Substituted azabicyclic compounds | Aventis Pharma Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7329675-B2 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20050038069-A1 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2005-02-17 | — | — | US | disclosed |
| US-6800645-B1 | INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LIMITED (GB) | 2004-10-05 | — | — | US | disclosed |
| US-20020173527-A1 | Substituted azabicyclic compounds | ASTLES PETER CHARLES (GB) | 2002-11-21 | — | — | US | disclosed |
| US-6303600-B1 | USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY | RHONE-POULENC RORER LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173527-A1 | Substituted azabicyclic compounds | CBR1, NOX1, POR | KDM4E 3056/4885TDP1 1839/4885POLB 1006/4885 |
| US-20050038069-A1 | Substituted azabicyclic compounds | NR2C2, NR3C1, NR3C2 | KDM4E 2408/4885TDP1 4815/4885POLB 2680/4885 |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | UGT1A1, CYP3A5, CYP3A7 | KDM4E 3851/4885TDP1 553/4885POLB 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.